Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: AUY922 Clear all
Completed Phase 2 Interventional Results available

A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.

NCT01124864
View directory record Official record
Conditions
Non-small-cell Lung Cancer
Interventions
AUY922
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Rockville, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Sep 3, 2026, 11:47 AM EDT
Terminated Phase 1 Interventional

Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies

NCT01602627
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Hsp90 inhibitor AUY922, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Dale Shepard, MD, PhD
Other
Eligibility
75 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Sep 3, 2026, 11:47 AM EDT
Terminated Phase 2 Interventional Results available

A Study of the HSP90 Inhibitor AUY922

NCT01485536
View directory record Official record
Conditions
Lymphoma
Interventions
AUY922
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 3, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor

NCT01404650
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
AUY922
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
New Haven, Connecticut • Fort Myers, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Sep 3, 2026, 11:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

NCT01259089
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Non-small Cell Lung Cancer
Interventions
erlotinib hydrochloride, Hsp90 inhibitor AUY922, laboratory biomarker analysis, needle biopsy, mutation analysis, pharmacological study
Drug · Other · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 3, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

AUY922 for Advanced ALK-positive NSCLC

NCT01752400
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
AUY922
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 3, 2026, 11:47 AM EDT
Completed Phase 1Phase 2 Interventional

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

NCT00526045
View directory record Official record
Conditions
Breast Cancer, Hematologic Neoplasms
Interventions
AUY922 2 mg/m2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
7
States / cities
Los Angeles, California • Augusta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 3, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

NCT01854034
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
AUY922
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 3, 2026, 11:47 AM EDT
Completed Phase 1 Interventional

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

NCT01613950
View directory record Official record
Conditions
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
Interventions
AUY922, BYL719
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 3, 2026, 11:47 AM EDT
Terminated Phase 2 Interventional Results available

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

NCT01646125
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer (NSCLC)
Interventions
AUY922, Docetaxel, Pemetrexed
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Rockville, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 3, 2026, 11:47 AM EDT
Terminated Phase 2 Interventional Results available

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

NCT01668173
View directory record Official record
Conditions
Myeloproliferative Neoplasms
Interventions
AUY922
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Sep 3, 2026, 11:47 AM EDT
Completed Phase 2 Interventional

Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

NCT01084330
View directory record Official record
Conditions
Advanced Gastric Cancer, Gastro-esophageal Junction Cancer
Interventions
AUY922, Docetaxel, Irinotecan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Los Angeles, California • Lafayette, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 3, 2026, 11:47 AM EDT
Completed Phase 1 Interventional Results available

A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

NCT01226732
View directory record Official record
Conditions
Metastatic or Unresectable Solid Tumor Malignancy
Interventions
Capecitabine, Hsp90 Inhibitor AUY 922
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Fort Myers, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Sep 3, 2026, 11:47 AM EDT
Completed Phase 1 Interventional

Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer

NCT01784640
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
Hsp90 inhibitor AUY922, pemetrexed disodium, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 3, 2026, 11:47 AM EDT
Terminated Phase 2 Interventional

Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

NCT01402401
View directory record Official record
Conditions
Advanced Gastric Cancer
Interventions
AUY922, Trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Los Angeles, California • Lake Success, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 3, 2026, 11:47 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

NCT00708292
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
AUY922, Bortezomib, Dexamethasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 3, 2026, 11:47 AM EDT
Completed Phase 1 Interventional

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

NCT01772797
View directory record Official record
Conditions
Anaplastic Lymphoma Kinase (ALK), Non-small Cell Lung Cancer
Interventions
LDK378, AUY922
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 3, 2026, 11:47 AM EDT
Completed Phase 1 Interventional

Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

NCT01294826
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions
AUY922, Cetuximab
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 3, 2026, 11:47 AM EDT
Completed Phase 1Phase 2 Interventional

Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

NCT01271920
View directory record Official record
Conditions
Advanced HER2-positive Breast Cancer
Interventions
AUY922, Trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 3, 2026, 11:47 AM EDT